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Abstract
Background: Although the Brazilian national reporting system for tuberculosis cases (SINAN) has enormous potential to
generate data for policy makers, formal assessments of treatment outcomes and other aspects of TB morbidity and
mortality are not produced with enough depth and rigor. In particular, the effect of HIV status on these outcomes has not
been fully explored, partly due to incomplete recording in the national database.
Methodology/Principal Findings: In a retrospective cohort study, we assessed TB treatment outcomes, including rates of
cure, default, mortality, transfer and multidrug resistant TB (MDR-TB) among a purposively chosen sample of 161,481 new
cases reported in SINAN between 2003 and 2008. The study population included all new cases reported in the six States
with the highest level of completeness of the HIV status field in the system. These cases were mostly male (67%), white
(62%), had pulmonary TB (79%) and a suspect chest X ray (83%). Treatment outcomes were best for those HIV negative
cases and worst for those known HIV positive patients (cure rate of 85.7% and 55.7% respectively). In multivariate modeling,
the risk of having an unfavorable outcome (all outcomes except cure) was 3.09 times higher for those HIV positive
compared with those HIV negative (95% CI 3.02–3.16). The risk of death and default also increased with HIV positivity. The
group without a known HIV status showed intermediate outcomes between the groups above, suggesting that this group
includes some with HIV infection.
Conclusions: HIV status played an important role in TB treatment outcomes in the study period. The outcomes observed in
those with known HIV were poor and need to be improved. Those in the group with unknown HIV status indicate the need
for wider HIV testing among new TB cases.
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Introduction
Tuberculosis and HIV represent major public health challenges
[1], although effective case management is currently available for
those who are detected. Integration of TB and HIV/AIDS
programs is needed in countries where this dual epidemic occurs,
but in practice few countries have implemented such coordinated
activities [2].
Brazil ranks as the 19
th country in the list of 22 high burden
countries (HBC) for tuberculosis, with an estimated number of cases
per year of around 71,000, with 4,800 deaths in TB patients each
year. In Brazil, TB is the third cause of death by infectious diseases
and the leading cause of death among AIDS patients [3]. The HIV
epidemic in Brazil has stabilized in recent years, with the prevalence
of HIV among adults (15 to 49 years old) remaining at about 0.6%
between 2000 and 2006. [4] Official figures from the Ministry of
Health indicate that in 2006 the estimated number of people living
with HIV/AIDS (PLWHA) was approximately 630,000 [4].
The World Health Organization (WHO) commented that TB
HIV collaborative activities are still not fully implemented in Brazil,
in spite of localized initiatives [2]. Although the Brazilian program
for HIV/AIDS was recognized internationally and tuberculosis has
been declared a priority by the Brazilian government in 2003, it is
observed that both programs’ recommendations were focused on
therapeutic regimens addressing the issue of interaction between
rifampicin and antiretroviral drugs. In both programs there were no
clear guidelines on how to reduce the burden of TB in PLWHA and
vice versa.Toillustratethisdelayinthe implementationofTB/HIV
collaborative activities in the country, we can highlight the fact that
in 2008, out of the 12 indicators of TB/HIV collaborative activities
recommended by the WHO [5], only three were available using
routinely collected information. The National TB Control Program
is currently undertaking a large scale project in the Southern region
of Brazil to foster these activities and demonstrate the impact that a
well-organizedandcoordinatedresponsetothedualepidemiccould
have.
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increases the likelihood of developing TB [6] and, if untreated, is
more likely to be associated with death while on TB treatment [7].
Moreover, the detection of HIV in TB patients enables access to
HIV care and treatment.
Furthermore,HIVinfluences the duration ofinfectiousness ofTB
[8]. HIV-infected individuals may have a shorter infectious period
due to a more rapid progression to TB disease. Alternatively, due to
a lackoftimelydiagnosis,theymaystayinfectiousforlongerthan an
individual without HIV. Therefore, TB infectiousness is related to
access to care and timely diagnosis of TB in PLWHA [8].
There are scarce data from large cohorts of patients entered into
the routine national reporting systems on the effect of HIV status
on TB treatment outcomes. We therefore conducted a study to
determine the TB treatment outcomes by category of HIV
serostatus of a cohort of all new cases of TB in Brazil, reported
between 2003 and 2008, including those whose test was requested
but not recorded and those in whom a test was not done.
Methods
Ethics statement
The databases were obtained under the rules for release of the
Secretariat of Health Surveillance and Health Care Department of
the Ministry of Health, ensuring the confidentiality and non-
disclosure of individual identifiers. The study was approved by the
Brazilian National Commission for Research Ethics and by the
International Union Against Tuberculosis and Lung Disease’s
Ethics Advisory Group (EAG).
Design
This was a retrospective cohort study consisting of record
reviews of data from the national TB reporting system (SINAN –
Sistema Nacional de Agravo de Notificac ¸a ˜o).
Setting
The study included six States of Brazil selected because they
include a large percentage of TB cases (37% in 2008) in the country
and they have a higher level (top quintile) of completeness of the
data on HIV status for TB cases in the national reporting system.
Between the beginning of the AIDS epidemic in Brazil and 2009,
these States also represented 62% of the AIDS cases reported in the
country [9]. States included were: Santa Catarina, Sa ˜o Paulo, Rio
Grande do Sul, Espirito Santo, Mato Grosso do Sul and Parana ´.
The standard TB treatment for new cases during the study period
was: 2 months of isoniazid, rifampicin and pyrazinamide followed
by 4 months of isoniazid and rifampicin (2 HRZ/4 HR). In Brazil,
anti-TB drugs are only provided by the public health system.
Patient Sample/Study Population
The study population included all new TB cases in the six
selected States in Brazil in the period from January 1, 2003 to
December 31, 2008, i.e., a total of 161,481 cases. The six-year
study period was chosen in order to evaluate a substantial number
of new TB cases and this represented a period during which the
Brazilian government declared TB to be a national public health
priority. The relatively long time span avoided potential short term
fluctuations in case reporting and was terminated in 2008 because
this was the most recent year for which final and consistent data
were available in SINAN.
Variables, data collection
A new case was defined as a TB case who was never treated
with anti-TB drugs for as much as one month; or those who had
completed previous TB treatment over 5 years ago. We excluded
those classified as retreatment cases, defined (in that time period,
2003 to 2008) as those who presented as a TB case and had
completed treatment less than 5 years ago [10].
A TB case was defined as a patient presenting one or two
positive sputum smears and/or a positive culture result. However,
if bacteriological exams were negative, one could be reported as a
TB case based on symptoms (such as cough for over 3 weeks, fever,
night sweats and weight loss), epidemiological history (having had
contact with a known TB patient) and complementary exams
suggesting the disease (chest X ray, tomography, tuberculin skin
test and histopathology exams) [10].
A patient was considered HIV infected when a screening HIV
test by Enzyme-Linked Immunoabsorbent Assay (ELISA) was
positive, followed by a confirmatory positive test. The confirma-
tion should be obtained by a second blood sample when a new
ELISA and an indirect immunofluorescence test or a western blot
were positive [11].HIV status was defined as positive, negative
(based on a recorded result in SINAN); HIV test requested but no
result recorded; or, HIV test not done. Information on HIV status
should be informed by the time the case gets reported, and it can
be updated during the course of treatment. The National
Tuberculosis Program (NTP) recommends that the epidemiolog-
ical surveillance services send requests to health services during the
course of treatment if they receive case notifications with the HIV
field either empty, or with no result. Cure was defined as
completed treatment with 2 negative smear microscopy examina-
tions (one during the course of treatment and one at the end) for
the pulmonary cases initially smear positive; or, based on clinical,
radiological and complementary examination criteria in those who
did not produce sputum for a smear examination. The latter
criterion was also applied for the extra-pulmonary cases (clinical
cure not bacteriologically confirmed).
A patient was defined as a defaulter if he or she did not come to
the health service for more than 30 days after the expected date of
consultation, and in the case of directly observed therapy (DOT),
the 30 day period started on the last day of observed drug intake.
Death was considered as the outcome when there was
knowledge of the patient’s death during the course of treatment,
regardless of cause of death. Multidrug-resistant tuberculosis
(MDR-TB) was defined as a case that was documented as resistant
to at least rifampicin and isoniazid after drug susceptibility testing.
All variables collected and used in this analysis came from the
informatics TB reporting system. Data were abstracted electron-
ically by Ministry of Health staff at central level, where
information flows from the lower levels (municipal and state)
and gets consolidated. Variables included sex, age, education, type
of TB, thoracic X ray reading, HIV status and TB treatment
outcomes. Data were abstracted between February and May of
2011.
Data Analysis and Statistics
Data were tabulated and proportions compared for categorical
variables using the Chi-square test. All the variables, considering
the number of missing data was not too substantial, such as
schooling and race, were examined for their association with the
outcome (to evaluate their potential as a predictor) and also
exposure (to identify potential confounders) for inclusion in the
multivariate models. Relative risks (RR) and relative risk ratios
with 95% confidence intervals (CI) were calculated using log
binomial [12] and multinomial logit models to determine
relationships using the softwares Stata
TM version 7 and R version
2.12.0.
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confounding and other associations between potential explanatory
variables and treatment outcomes. Any such variable was included
in the models, along with the state of residence. As Sa ˜o Paulo State
accounted for a high proportion of cases in the dataset, we
determined whether adjusting for this variable affected the
detected differences and associations.
In order to analyze the treatment outcome patterns, we had two
different approaches. The first one compared cure rates against all
other outcomes, defined as unfavorable. The second one looked at
default and death separately, in relation to those who were cured.
The second model considered three levels of the outcome (cure,
default and death), as opposed to the first one when we looked at
cure versus all other outcomes, considered unfavorable. This way
we were also able to examine the effect of HIV status separately on
default and death. We included type of TB and age in the model,
as per the strategy defined above. In addition, an interaction term
between type of TB and HIV status was tested. Relative risk ratios
were obtained comparing HIV positives to negatives, and the
result was the factor by which the relative risk for default
compared to cure was expected to change, given that the other
variables in the model were held constant. The same procedure
was carried out for death compared to cure.
Sample size considerations
All patients meeting the inclusion criteria (new TB cases) in the
study period in the selected States were included in the study.
Results
A total of 161,481 new TB cases were reported to SINAN
between 2003 and 2008 in the selected States. Basic demographic
and clinical characteristics of the cases are reported in table 1. A
majority of cases (67%) were males, almost 40% had less than 8
years of education and almost 80% had pulmonary TB. A high
proportion of the cases were reported in the State of Sa ˜o Paulo
(59%). Of the total study population, 68% (109,820) was known to
have been HIV tested, of whom 20,881 were HIV-positive (19%
of those tested) and 88,939 were HIV-negative. Of those with no
HIV result, 10,567 had a test requested but no result was available
and in the remainder the HIV test was not done. Seventy-eight
percent of all cases had a smear microscopy exam done, and
70.6% of those had a positive result. As far as culture, 19.7% had a
result for it, and 65% of those were positive.
TB treatment outcomes were best for those who were known to
be HIV negative and worst for those known to be HIV positive
(see table 2). TB treatment outcomes for those in whom an HIV
test was requested but the result was not available were better than
those in whom the test was not done.
In bivariate analyses, in reference to the HIV negative group,
patients with a positive HIV-status or unknown HIV status had a
higher probability of having an adverse treatment outcome (risk
ratios ranged from 1.7 to 3.1, all p-values,0.05).
Type of TB was also associated with HIV status. Those who
were HIV positive had a higher risk of presenting extrapulmonary
and disseminated forms than the pulmonary form, when
compared to HIV negative patients (RR 2.08, 95% CI 2.02–
2.13; and 3.15, 95% CI 3.05–3.26 respectively – see table 3).
In the first multivariate model, HIV positive TB cases were 3
times more likely (adjusted risk ratio 3.09, 95% CI 3.02–3.16) to
have an unfavorable outcome, when compared to HIV negative
TB patients. Risk ratios for patients with no HIV test results
confirmed the associations already shown in table 2. The risk
ratios of an unfavorable outcome for the groups with HIV test
requested but with no result recorded, and those without an HIV
test, again using the HIV negative group as the reference, were
1.71 (95% CI 1.64–1.78) and 2.09 (95% CI 2.05–2.14)
respectively.
The inclusion of the variable related to state of residence did not
significantly change the point estimates for the risk ratios derived
from the model or the direction of the observed association.
The proportion of patients with known HIV status increased
overtime, from 62% in 2003 to 74% in 2008, whereas the group
without an HIV test done decreased from 31% to 21% by the end
of the study period. Nevertheless, the cure, default and death rates
for both HIV positive and negative groups remained stable
overtime (figure 1).
In the second multivariate model, using cure as the reference
group, death was shown to get an increase in RR by a factor of
9.24 with HIV positivity (95% CI 8.78–9.72), whereas this factor is
2.88 (95% CI 2.74–3.03) when we looked at default. In other
words, if a patient is HIV positive, the relative risk for default
compared to cure, and death compared to cure, would be
expected to increase by a factor of 2.88 and 9.24 respectively,
given the other variables in the model are held constant. The
interaction term between type of TB and HIV status proved to
have no significant effect on the model estimates.
Table 1. Characteristics of new tuberculosis cases in 6 States
of Brazil between the years of 2003 and 2008 (n=161481).
+
N( % )




Education (years of study)
0 to 4 22076 (13.7)
5 to 8 42152 (26.1)
9 to 11 21989 (13.6)






Mixed (mulatto) 14492 (16.5)
Indigenous 1224 (1.4)
Not provided 7306 (8.3)
Type of TB
Pulmonary 127260 (78.8)
Extra pulmonary 27654 (17.1)




Other pathology 2162 (1.4)
Not done 14159 (9.2)
+Data are presented as actual numbers and proportions for categorical
variables, and median (and interquartile ranges) for continuous variables.
doi:10.1371/journal.pone.0033129.t001
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Our study showed a striking difference in TB treatment
outcomes between those known to be HIV positive and those
known to be HIV negative with intermediate levels of treatment
success in those with unknown HIV status. Moreover, a substantial
proportion of TB cases did not have an HIV test result recorded
(either not recorded in the system or not done), which falls short of
recommended levels for HIV testing.
The fact that cure, default and death rates for both HIV positive
and negative groups remained stable overtime deserves attention.
These results indicate little progress in the implementation of TB/
HIV collaborative activities, and that only the offer of HIV testing
for TB patients is not sufficient for therapeutic success, and
reinforces the need to ensure the provision of comprehensive care
to co-infected patients. In addition, the national guidelines for TB/
HIV case management during the study period [10] remained
unchanged, and recommended to prioritize TB treatment, and
only after clinical improvement the patient was evaluated for
eligibility for antiretroviral therapy (ART), by performing CD4 cell
count and viral load tests. This approach caused delays in
initiating ART in TB patients who, by current guidelines, would
be eligible for it [13].
The TB treatment outcomes in those known to be HIV positive
were relatively poor, with low cure rates and high death rates. A
recent study compiled results from several other studies on the
effect of HIV co-infection on the outcome of TB treatment [14].
These studies were smaller, not population based and used
regimens slightly different than that used in Brazil during the study
period, and the cure rates observed ranged from 57% to 91%. Of
note, in 4 of these studies the patients were not on antiretroviral
treatment (ART) and the cure rate was close to 80%. We have no
information about ART usage in the patients in our study, but
even assuming a worst case scenario where no patient was placed
on ART, the observed outcome was not very satisfactory. Death
rates in these smaller studies were also high, but in some of these
studies follow-up continued beyond the end of anti-TB treatment,
while in our study we assessed treatment outcomes only during the
course of anti-TB treatment.
The intermediate treatment success noted in those in whom the
HIV test result was unknown (either not recorded or not done)
suggests that this group of patients contained a proportion who
were HIV positive who might have benefited from integrated HIV
and TB care, if their results had been known and high quality of
HIV care offered to them.
The States included in this study are considered to be States with
a better than average health care system, especially Sa ˜o Paulo and
the three States from the Southern Region (Rio Grande do Sul,
Santa Catarina and Parana ´). These are not considered as
representative of the country as a whole. Despite this, the cure
ratefornew TBcasesthatwereknownHIVpositiveat55%waslow
compared with that observed in patients who were HIV-negative.
We do not know the reasons for this as there were no data available
in the TB national system on modalities of HIV care and ART
usage. Although this is a limitation of our study, it points to the need
for future research that can potentially be carried out by linkage of
national TB and HIV/AIDS programs databases on a national
level. Work has previously been carried out in Brazil on the effect of
ART on outcomes of people living with HIV and the effect of ART
on TB incidence [15,16] and on factors associated with co-infection
itself [17,18]. However, less attention has been paid to the effect of
HIV status on TB treatment outcomes. Two cohort studies [19,20]
looked at the influence of HIV infection on mortality of patients
undergoing TB treatment in Rio de Janeiro, and their findings
confirm the increased mortality risk for HIV positive individuals not
on ART as compared to HIV negative patients. In addition, one of
them showed an excess risk, although not statistically significant, of
mortality when comparing HIV positive patients on ART to HIV
negativepatients [20]. Thesefindings areconsistentwith ourresults.
A possible explanation, confirmed in these two cohort studies
[19,20], is the higher clinical severity of disease at presentation. In
our study, we also showed that those with worse outcomes,
including increased mortality, were the HIV positive individuals,
and these were more likely to present extrapulmonary and
Table 2. TB treatment outcomes by HIV status in new TB cases diagnosed in 6 States of Brazil between 2003 and 2008.
TB treatment outcomes
HIV Status Total (N) Cure (N, %) Default (N, %) Death (N, %) Transfer (N, %) MDR-TB (N, %)
Negative 87693 75185 (85.7) 6185 (7.0) 3652 (4.2) 2608 (3.0) 63 (0.07)
Positive 20426 11369 (55.7) 2792 (13.7) 4705 (23.0) 1536 (7.5) 24 (0.12)
Test requested but no result recorded 10035 7568 (75.4) 1166 (11.6) 736 (7.3) 563 (5.6) 2 (0.02)
Test not done 40043 27953 (69.8) 4570 (11.4) 5016 (12.5) 2478 (6.2) 26 (0.06)
Total 158197 122075 (77.2) 14713 (9.3) 14109 (8.9) 7185 (4.5) 115 (0.07)
doi:10.1371/journal.pone.0033129.t002
Table 3. Form of TB presentation by HIV status among new TB cases diagnosed in selected States of Brazil between 2003 and
2008 (n=109815).
HIV status Form of TB Total (N, %)
Pulmonar (N, %) Extrapulmonar (N, %) Disseminated (N, %)
HIV negative 72216 (81.2) 13915 (15.6) 2805 (3.2) 88936 (100)
HIV positive 12390 (59.3) 6078 (29.1) 2411 (11.6) 20879 (100)
doi:10.1371/journal.pone.0033129.t003
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time of TB diagnosis among those HIV infected can be a
consequence of missed opportunities by the health care system to
provide the diagnosis orofdelaysinthe patientseeking caretoavoid
receiving a positive HIV result [18].
Overall the group of patients without an HIV test done had worse
treatment outcomes than the group in which a test was requested but
no resultwas recorded in the public health system. This observation is
not easily explained and warrants an in depth investigation of the
profile of each group, ideally by obtaining the actual HIV status of
these patients or gathering information on whether the test was
carried out or not. This analysis is beyond the scope of this paper.
Another important point that came out of our study was the
treatment outcome of patients without a known HIV status.
Regardless of whether the test was requested or not, the outcomes
were at an intermediate level between the HIV positive and
negative groups. This indicates that there were probably HIV
infected TB patients among this group, resulting in their treatment
outcomes being different from the HIV negative group. There was
no difference in the distribution of any other variables when these
groups were compared. Therefore, the unknown variable, i.e.,
HIV status, might be responsible for the observed pattern. This
finding has important policy and programmatic implications. The
offering of HIV testing for new TB cases is supposed to be
universal, but our finding demonstrates that this does not occur. It
is of concern that this situation was detected in States with a fairly
good health services organization and some degree of integration
between TB and HIV Programs. Of the 6 states participating in
the study only Sao Paulo published a decree in 1998 [21], which
recommends the provision of anti HIV testing for all TB patients
and also recommends the establishment of a flow between the TB
and HIV/AIDS health units for the comprehensive care of co-
infected patients. During the study period we did not observe any
additional actions to increase HIV testing in TB services beyond
the national recommendations. Moreover, HIV testing for TB
patients was not performed in the TB clinic, and therefore had to
rely on the willingness of the individual to seek testing elsewhere
(laboratory or center for anonymous HIV testing). Obviously,
there is a long way to go to ensure that all TB cases are tested for
HIV, and as important as the testing itself, that this information
makes its way into the national reporting system.
To improve the outcomes mentioned above, the National HIV/
AIDS Program officially recommended rapid testing for HIV
diagnosis in 2009, making HIV testing available at TB services
[22]. In 2010, both TB and HIV/AIDS Programs issued
guidelines defining the HIV/AIDS services as the reference for
treatment of co-infected patients [23]. The expected consequence
of such strategies will be an increase in the proportion of TB cases
tested for HIV and an improvement of success rates of TB
treatment in TB/HIV co-infected cases. Future studies will allow
us to confirm if these policies, not present during our study period,
had the expected result.
Our study is a very large study and evaluates a substantial
proportion of the population of Brazil. It strongly confirms that the
access to HIV testing is not as high as it should be, even though the
States studied would have been expected to perform well in this
regard. It is possible that these results reflect the situation in many
similar countries with a high TB and HIV burden.
One limitation of our study is that we did not have access to
ART history among our group of HIV co-infected patients. It is
likely though that most of them were not receiving ART and care
or were diagnosed late in the course of their HIV disease. The
large proportion of deaths in this group reinforces this hypothesis.
Another limitation is that the study covered only some of the States
in the country. Hence, it cannot be interpreted as representative of
the whole country. In addition, since we were dealing with patient-
level data, we could not examine health system related variables,
such as quality of the care provided by the facility, coverage of the
Family Health Programs and DOTS strategy in the area where
the patient lived. Nevertheless, since we intentionally chose States
with good completeness of data, which in turn is a reasonable
marker for a well-organized service, it is of concern that the
situation we assessed is far from optimal.
Information on DOT could not be included in the analysis due
to the limited availability of information on this variable in the
database. Until 2007, the only field in the TB case report form
related to DOT indicated that it was recommended for that
patient, but there was no confirmation that it was actually carried
out throughout the treatment. During the study period, the
number of drug intake events that should be observed to consider
that patient as having had DOT completed was defined as three
weekly observations during the intensive phase and one weekly
during the continuation phase [10]. In 2010 the NTP released its
revised National Guidelines [23], stating that DOT is defined as at
least 3 weekly observations both during the intensive and
continuation phases of treatment. This definition has been also
Figure 1. Treament outcomes (cure, default and death) for new TB cases by HIV status, Brazil 2003–2008. This figure shows the
proportion of new TB cases and their outcomes, by year, during the study period. It demonstrates that these proportions remain stable, at different
levels for each of the outcomes, over the 6-year period, for both HIV positive and HIV negative patients. It also highlights the differences by HIV
status, especially regarding cure and death rates.
doi:10.1371/journal.pone.0033129.g001
Outcome of TB Treatment by HIV Status in Brazil
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e33129refined stating that the choice and strategy for DOT needs to be
defined taking into consideration the patient, health staff and the
structure of the health service responsible for that individual’s
treatment. Data from the NTP indicate that in 2009 nationally,
the cure rate for those TB cases on DOT was 77.3%, compared to
68.7% for those patients not on DOT. The latter group had also
higher default (11.2%) than the former (7.1%) [3]. It will be of
interest to repeat this analysis in the future using data from a
period when the revised definition of DOT will be fully
implemented throughout the country.
The results of our study indicate the need to urgently implement
the TB/HIV collaborative activities, which in turn will improve
the care of co-infected patients. More patients need to be HIV-
tested. It is also essential to evaluate the quality of care of those
known to be HIV positive to determine if the unfavorable
outcomes of treatment can be improved through better HIV care
and treatment, if so to extend this care to all those who are HIV
positive.
Conclusion
Care for HIV infected new TB cases needs to be closely
monitored by health authorities in Brazil to guarantee that this
group accesses the benefits that therapy can bring. In addition,
HIV testing needs to become effectively universal for new TB
cases, so that the care mentioned above can be provided in a
comprehensive and timely manner. Finally, it is likely that a
certain proportion of TB patients are HIV-tested but the results
are not being documented in the routine information systems,
which points out to the need for more training and awareness from
all health professionals to properly document these actions. This is
the only way to generate the solid evidence policy makers need to
make decisions that will improve health outcomes for the
populations that need care.
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